Protein zapper: new drug targets breast cancer from the inside

NCT ID NCT07697443

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial investigates TQB3126, a drug designed to destroy specific proteins that help breast cancer grow. It involves adults with breast cancer whose disease has worsened after prior treatments. The study will first find the safest dose and then test how well it works, alone or with other therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TQB3126 (a targeted protein degrader)
What this could lead to
If successful, this could provide a new treatment option for breast cancer by breaking down cancer-driving proteins.
What could go wrong
This is an early-phase trial, so the drug may not work or could cause side effects. It is not a cure and requires ongoing management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Meizhou People's Hospital

    Meizhou, Guangdong, 514000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510288, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, 410000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, 300202, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, 430000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.